Press Releases April 21, 2026 04:05 PM

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

OPKO Health to announce Q1 2026 financial results and provide business update on April 28, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
OPK

OPKO Health, a biopharmaceutical and diagnostics company, will report its operating and financial results for Q1 2026 on April 28 after the U.S. market close. The company will hold a conference call and webcast to discuss the results and provide financial guidance.

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
OPK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OPKO Health will release Q1 2026 financial results on April 28, 2026.
  • Senior management will provide a business update and financial guidance during a conference call and webcast.
  • The company operates in biopharmaceuticals and diagnostics, targeting large and rapidly growing markets.

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.

A telephone replay will be available until May 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2140261. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.

Contacts:

Alliance Advisors IR
Yvonne Briggs, 310-691-7100
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]


Risks

  • Financial and operational results may fail to meet market expectations, affecting stock performance.
  • The highly competitive biopharmaceutical and diagnostics industry and regulatory environment pose ongoing challenges.
  • Future financial guidance may involve uncertainties related to market conditions and product development outcomes.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026